CD44 and glioma: Additionally, changes in luminescence after the mice were treated with different formulations showed that treatment with Fe3O4@T7/AS1411-SKN/DTX significantly inhibited CD133+ and CD44+ cells within glioma segments, further underscoring the effectiveness of dual-ligand modification in glioma-specific inhibition.